Literature DB >> 25011696

Modelling the structure of full-length Epstein-Barr virus nuclear antigen 1.

Mushtaq Hussain1, Derek Gatherer, Joanna B Wilson.   

Abstract

Epstein-Barr virus is a clinically important human virus associated with several cancers and is the etiologic agent of infectious mononucleosis. The viral nuclear antigen-1 (EBNA1) is central to the replication and propagation of the viral genome and likely contributes to tumourigenesis. We have compared EBNA1 homologues from other primate lymphocryptoviruses and found that the central glycine/alanine repeat (GAr) domain as well as predicted cellular protein (USP7 and CK2) binding sites are present in homologues in the Old World primates, but not the marmoset, suggesting that these motifs may have co-evolved. Using the resolved structure of the C-terminal one-third of EBNA1 (homodimerization and DNA binding domain), we have gone on to develop monomeric and dimeric models in silico of the full-length protein. The C-terminal domain is predicted to be structurally highly similar between homologues, indicating conserved function. Zinc could be stably incorporated into the model, bonding with two N-terminal cysteines predicted to facilitate multimerisation. The GAr contains secondary structural elements in the models, while the protein binding regions are unstructured, irrespective of the prediction approach used and sequence origin. These intrinsically disordered regions may facilitate the diversity observed in partner interactions. We hypothesize that the structured GAr could mask the disordered regions, thereby protecting the protein from default degradation. In the dimer conformation, the C-terminal tails of each monomer wrap around a proline-rich protruding loop of the partner monomer, providing dimer stability, a feature which could be exploited in therapeutic design.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25011696     DOI: 10.1007/s11262-014-1101-9

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  72 in total

1.  Two domains of the epstein-barr virus origin DNA-binding protein, EBNA1, orchestrate sequence-specific DNA binding.

Authors:  J Cruickshank; K Shire; A R Davidson; A M Edwards; L Frappier
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

2.  The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes.

Authors:  John Sears; Maki Ujihara; Samantha Wong; Christopher Ott; Jaap Middeldorp; Ashok Aiyar
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  RNA-dependent recruitment of the origin recognition complex.

Authors:  Julie Norseen; Andreas Thomae; Venkatesh Sridharan; Ashok Aiyar; Aloys Schepers; Paul M Lieberman
Journal:  EMBO J       Date:  2008-10-23       Impact factor: 11.598

4.  Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA.

Authors:  A Bochkarev; J A Barwell; R A Pfuetzner; E Bochkareva; L Frappier; A M Edwards
Journal:  Cell       Date:  1996-03-08       Impact factor: 41.582

5.  I-TASSER: a unified platform for automated protein structure and function prediction.

Authors:  Ambrish Roy; Alper Kucukural; Yang Zhang
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

6.  A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.

Authors:  J Yates; N Warren; D Reisman; B Sugden
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

7.  Epstein-Barr virus nuclear antigen 1 Hijacks the host kinase CK2 to disrupt PML nuclear bodies.

Authors:  Nirojini Sivachandran; Jennifer Yinuo Cao; Lori Frappier
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

8.  Enhanced malignant progression of nasopharyngeal carcinoma cells mediated by the expression of Epstein-Barr nuclear antigen 1 in vivo.

Authors:  L F Sheu; A Chen; C L Meng; K C Ho; W H Lee; F J Leu; C F Chao
Journal:  J Pathol       Date:  1996-11       Impact factor: 7.996

Review 9.  Intrinsically disordered proteins: regulation and disease.

Authors:  M Madan Babu; Robin van der Lee; Natalia Sanchez de Groot; Jörg Gsponer
Journal:  Curr Opin Struct Biol       Date:  2011-04-20       Impact factor: 6.809

Review 10.  Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival.

Authors:  Lori Frappier
Journal:  Viruses       Date:  2012-09-13       Impact factor: 5.818

View more
  10 in total

1.  Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.

Authors:  Julianna S Deakyne; Kimberly A Malecka; Troy E Messick; Paul M Lieberman
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

2.  Ubiquitin-specific peptidase 7 (USP7)-mediated deubiquitination of the histone deacetylase SIRT7 regulates gluconeogenesis.

Authors:  Lu Jiang; Jiannan Xiong; Junsi Zhan; Fengjie Yuan; Ming Tang; Chaohua Zhang; Ziyang Cao; Yongcan Chen; Xiaopeng Lu; Yinglu Li; Hui Wang; Lina Wang; Jiadong Wang; Wei-Guo Zhu; Haiying Wang
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

3.  Cryo-EM Structure and Functional Studies of EBNA1 Binding to the Family of Repeats and Dyad Symmetry Elements of Epstein-Barr Virus oriP.

Authors:  Yang Mei; Troy E Messick; Jayaraju Dheekollu; Hee Jong Kim; Sudheer Molugu; Leonardo Josué Castro Muñoz; Vera Moiskeenkova-Bell; Kenji Murakami; Paul M Lieberman
Journal:  J Virol       Date:  2022-08-29       Impact factor: 6.549

Review 4.  Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma.

Authors:  Pok Man Hau; Hong Lok Lung; Man Wu; Chi Man Tsang; Ka-Leung Wong; Nai Ki Mak; Kwok Wai Lo
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

Review 5.  Epstein-Barr virus and multiple sclerosis.

Authors:  Samantha S Soldan; Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2022-08-05       Impact factor: 78.297

6.  Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2.

Authors:  Mushtaq Hussain; Anusha Amanullah; Ayesha Aslam; Fozia Raza; Shabana Arzoo; Iffat Waqar Qureshi; Humera Waheed; Nusrat Jabeen; Sanya Shabbir; Muneeba Ahsan Sayeed; Saeed Quraishy
Journal:  Polymers (Basel)       Date:  2022-08-10       Impact factor: 4.967

Review 7.  EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.

Authors:  Joanna B Wilson; Evelyne Manet; Henri Gruffat; Pierre Busson; Marc Blondel; Robin Fahraeus
Journal:  Cancers (Basel)       Date:  2018-04-06       Impact factor: 6.639

8.  STUB1 is targeted by the SUMO-interacting motif of EBNA1 to maintain Epstein-Barr Virus latency.

Authors:  Yuyan Wang; Shujuan Du; Caixia Zhu; Chong Wang; Nuoya Yu; Ziqi Lin; Jin Gan; Yi Guo; Xinxin Huang; Yuping He; Erle Robertson; Di Qu; Fang Wei; Qiliang Cai
Journal:  PLoS Pathog       Date:  2020-03-16       Impact factor: 6.823

9.  Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site.

Authors:  Kinga Csorba; Lucia A Schirmbeck; Eylul Tuncer; Camillo Ribi; Pascale Roux-Lombard; Carlo Chizzolini; Uyen Huynh-Do; Dominique Vanhecke; Marten Trendelenburg
Journal:  Front Immunol       Date:  2019-11-07       Impact factor: 7.561

10.  Reactivation of Epstein-Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn2+-chelating function.

Authors:  Lijun Jiang; Hong Lok Lung; Tao Huang; Rongfeng Lan; Shuai Zha; Lai Sheung Chan; Waygen Thor; Tik-Hung Tsoi; Ho-Fai Chau; Cecilia Boreström; Steven L Cobb; Sai Wah Tsao; Zhao-Xiang Bian; Ga-Lai Law; Wing-Tak Wong; William Chi-Shing Tai; Wai Yin Chau; Yujun Du; Lucas Hao Xi Tang; Alan Kwok Shing Chiang; Jaap M Middeldorp; Kwok-Wai Lo; Nai Ki Mak; Nicholas J Long; Ka-Leung Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-10       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.